Spark Therapeutics Inc (NASDAQ:ONCE) – Stock analysts at B. Riley increased their FY2020 earnings per share (EPS) estimates for shares of Spark Therapeutics in a research report issued on Wednesday, November 7th. B. Riley analyst M. Kumar now expects that the biotechnology company will earn $1.78 per share for the year, up from their prior forecast of $1.75. B. Riley currently has a “Buy” rating and a $71.00 target price on the stock. B. Riley also issued estimates for Spark Therapeutics’ FY2021 earnings at $3.56 EPS and FY2022 earnings at $3.59 EPS.
A number of other equities research analysts have also recently weighed in on ONCE. Zacks Investment Research cut Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. ValuEngine upgraded Spark Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, November 1st. Wedbush upgraded Spark Therapeutics from an “underperform” rating to a “neutral” rating and set a $40.00 price target on the stock in a report on Wednesday. They noted that the move was a valuation call. Mizuho lowered their price target on Spark Therapeutics to $62.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Cantor Fitzgerald set a $103.00 price target on Spark Therapeutics and gave the stock a “buy” rating in a report on Monday, July 16th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $68.52.
Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.22). The firm had revenue of $10.70 million during the quarter, compared to analyst estimates of $27.44 million. Spark Therapeutics had a negative return on equity of 14.34% and a negative net margin of 127.82%. The business’s revenue was up 463.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.90) EPS.
Several institutional investors have recently modified their holdings of the business. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Spark Therapeutics in the 3rd quarter worth $122,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Spark Therapeutics in the 2nd quarter worth $203,000. Cubist Systematic Strategies LLC purchased a new position in shares of Spark Therapeutics in the 2nd quarter worth $268,000. Bank of Montreal Can raised its position in shares of Spark Therapeutics by 1,045.4% in the 3rd quarter. Bank of Montreal Can now owns 3,253 shares of the biotechnology company’s stock worth $177,000 after buying an additional 2,969 shares during the period. Finally, Smith Asset Management Group LP raised its position in shares of Spark Therapeutics by 39.6% in the 3rd quarter. Smith Asset Management Group LP now owns 3,950 shares of the biotechnology company’s stock worth $215,000 after buying an additional 1,120 shares during the period.
About Spark Therapeutics
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.
Featured Story: Reverse Stock Split
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.